Ignite Creation Date:
2025-12-24 @ 2:50 PM
Ignite Modification Date:
2026-02-02 @ 3:04 AM
Study NCT ID:
NCT05188859
Status:
RECRUITING
Last Update Posted:
2025-05-31
First Post:
2021-12-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
NCC2950
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None